Brief: Optinose Inc Says FDA Approved Hikma As Additional Manufacturing Site For Finished XHANCE Units For Commercial Sale And Sampling
14/03/2024 21:41
March 14 (Reuters) - OptiNose Inc OPTN.O :
* OPTINOSE INC: ON MARCH 9, FDA APPROVED HIKMA, AS
ADDITIONAL
MANUFACTURING SITE FOR FINISHED XHANCE UNITS FOR COMMERCIAL SALE
AND SAMPLING
Source text for Eikon: ID:n0001494650-24-000029
Further company coverage: OPTN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OptiNose
See all newsOptiNose Inc reports results for the quarter ended March 31 - Earnings Summary
OptiNose Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: OptiNose Q4 Income From Operations USD 354 Thousand
U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose
U.S. STOCKS ON THE MOVE-Accenture, Nike, FedEx